On heels of positive data for ATTR drug, Alnylam looks to raise more capital — nearly $1B worth
A week after presenting positive data on its drug for treating the heart failure condition called transthyretin-mediated amyloidosis (ATTR) with cardiomyopathy, Alnylam wants to get almost $1 billion in new money.
The company announced that it was offering a $900 million principal amount of convertible senior notes due 2027. Convertible notes are short-term debt that converts into equity.
“The offering of the notes is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering,” the company said in a press statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.